Loading…
Tianjin-based heritage traditional-Chinese-medicine (TCM) manufacturer and retail pharmacy group.
Tianjin-based heritage traditional-Chinese-medicine (TCM) manufacturer and retail pharmacy group.
Earns from branded traditional-Chinese-medicine pills and granules sold through pharmacies and hospitals, plus the margin on a pharmacy chain that also sells other makers' products. Herbal ingredients are the main input cost.
Moat: narrow (brand). Century-old heritage TCM brand with established consumer trust.
Headquarters: Tianjin, China · Employees: 3,890
Size Tianjin Pharmaceutical Da Ren Tang (600329.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.11B, the 622nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥42.12 on 6 Nov 2026.
Performance Over six months the shares gained 3.7%, against +4.5% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 12.8% over the last twelve months (peer median +7.9%); the operating margin is 20.4% (peer median 15.7%).
Valuation It trades at 31.4× forward earnings against a peer median of 25.1× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.9 points above its cost of capital (8.8% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.67B | CN¥4.86B | CN¥7.23B | CN¥8.17B | CN¥8.19B |
| Revenue growth | — | -33% | -11% | 0% | — |
| Gross profit | CN¥3.55B | CN¥3.52B | CN¥3.37B | CN¥3.50B | CN¥3.18B |
| EBITDA | n/a | CN¥1.04B | CN¥891M | CN¥892M | CN¥779M |
| Net income | CN¥896M | CN¥2.13B | CN¥2.23B | CN¥987M | CN¥862M |
| Free cash flow | CN¥686M | CN¥378M | CN¥1.16B | CN¥726M | CN¥776M |
| Capital expenditure | CN¥134M | CN¥119M | CN¥118M | CN¥141M | CN¥108M |
| Total debt | CN¥94.9M | CN¥76.9M | CN¥54.8M | CN¥840M | CN¥939M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% |
| Beijing TongRenTang 600085.SS | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | $4.61B | -11% | +1% | 3% | 13.3× | -0.3% |
| Tasly Pharmaceutical 600535.SS | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yifeng Pharmacy Chain 603939.SS | $4.91B | +17% | +5% | 10% | 17.2× | -9.2% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600329.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.5% | +6.1% | 3rd highest of 21 |
| 6-month return | +3.7% | +4.5% | 10th lowest of 21 |
| Distance from 52-week high | -17.3% | -26.1% | 7th highest of 21 |
| Revenue growth (TTM) | -12.8% | +7.9% | 3rd lowest of 20 |
| Operating margin | 20.4% | 15.7% | 7th highest of 19 |
| Forward P/E | 31.4× | 25.1× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 17.8% | 5.0% | 4th most demanding of 16 |
| Growth delivered (Del g) | -5.8% | +7.5% | lowest of 16 |
| Hurdle (Req g minus delivered) | +23.7 pp | -3.3 pp | most demanding of 16 |
| ROIC minus cost of capital | +6.9 pp | +7.6 pp | 9th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% | +4.0% |